Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Equivalents (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Cash & Equivalents for 5 consecutive years, with $41.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 18.69% to $41.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.3 million through Dec 2025, down 18.69% year-over-year, with the annual reading at $41.3 million for FY2025, 18.69% down from the prior year.
  • Cash & Equivalents hit $41.3 million in Q4 2025 for ARS Pharmaceuticals, down from $59.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $374.2 million in Q1 2021 to a low of $36.6 million in Q2 2024.
  • Historically, Cash & Equivalents has averaged $133.7 million across 5 years, with a median of $65.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 250.5% in 2022 and later crashed 70.21% in 2023.
  • Year by year, Cash & Equivalents stood at $60.1 million in 2021, then soared by 250.5% to $210.5 million in 2022, then plummeted by 66.29% to $71.0 million in 2023, then decreased by 28.4% to $50.8 million in 2024, then fell by 18.69% to $41.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SPRY at $41.3 million in Q4 2025, $59.6 million in Q3 2025, and $51.5 million in Q2 2025.